Cancer

Patient sample and mouse studies suggest inhibiting the pentose phosphate pathway with PP2A inhibitor LB-100, inhibition of G6PD or synergistic combination of both, could help treat B cell ALL, B cell lymphoma and MCL. In tumor samples from patients with B cell ALL and B cell lymphoma, LB-100 or a tool compound G6PD inhibitor increased tumor cell death compared with vehicle. In tumor samples from B cell ALL, B cell lymphoma and MCL patients, the combination therapy increased cell death compared with either agent alone. In a patient-derived xenograft (PDX) mouse model of B cell lymphoma, LB-100 plus the G6PD inhibitor increased tumor cell death. Next steps include testing LB-100 in patients with B cell ALL, B cell lymphoma and MCL...